Details of the Drug Pharmacogenomic Perturbation Atlas
General Information of Drug (ID: DMQJSF9)
| Drug Name | ||||||
|---|---|---|---|---|---|---|
| Synonyms |
TAXIFOLIN; (+)-Taxifolin; dihydroquercetin; Distylin; Taxifoliol; (2R,3R)-Dihydroquercetin; (+)-Dihydroquercetin; TAXIFOLIN-(+); Lavitol; Lariksin; taxifolin (dihydroquercetin); 3,5,7,3',4'-Pentahydroxyflavanone; UNII-9SOB9E3987; trans-Dihydroquercetin; 4H-1-Benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-2,3-dihydro-3,5,7-trihydroxy-, (2R,3R)-; (+)-trans-Taxifolin; (2R,3R)-2-(3,4-DIHYDROXYPHENYL)-3,5,7-TRIHYDROXY-2,3-DIHYDRO-4H-CHROMEN-4-ONE; (2R,3R)-3,3',4',5,7-Pentahydroxyflavanone
| |||||
| Cross-matching ID | ||||||
Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
|
|
||||||||||||||||
|
||||||||||||||||
Pharmacogenomic Perturbation Across Diseases and Tissues
|
Breast
Breast adenocarcinoma
Colon
Colorectal adenocarcinoma
Kidney
Normal (Immortalized)
Liver
Hepatoblastoma
Lung
Lung adenocarcinoma
Peripheral blood
T-cell acute lymphoblastic leukemia
Prostate
Prostate carcinoma
Skin
Melanoma
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
